Case Report



Medicine

Pseudothrombocytopenia due to platelet aggregates in an infant: A case report

Pseudotrombocitopenia por agregados plaquetarios en lactante menor: Un reporte de caso

Esteban Artunduaga-Cañas[†] Esteban Pineda Arias , Juan Sebastián Arango Duque Estefanía Rivera Velásquez , Juan Diego Rivera Villota and Diego Fernando López Muñoz[†]

Open Access

Correspondence: dflopez@uceva.edu.co esteban.artunduaga01@uceva.edu.co Research Seminar on Infectious Diseases-EINTRANS. Health Sciences Faculty. Unidad Central del Valle del Cauca, Tulua-Valle del Cauca, Colombia.

First draft submitted: 15-07-2023 Accepted for publication: 27-11-2023 Published on line: 01-12-2023

Key words:

Ethylenediaminetetraacetic acid (EDTA); autoantibodies; platelet aggregation; Pseudothrombocytopenia; thrombocytopenia.

Palabras clave:

Ácido de Etilenodiaminetetraacético (EDTA); agregación plaquetaria; autoanticuerpos; Pseudothrombocytopenia; Trombocitopenia,

Citation:

Artunduaga-Cañas E., Pineda Arias E., Arango Duque JS., Rivera Velásquez E., Rivera Villota JD., López Muñoz DF. Pseudothrombocytopenia due to platelet aggregates in an infant: A case report. *Magna Scientia UCEVA* 2023; 3:2, 143-149. *https://doi.org/10.54502/msuceva. v3n2a3*

Abstract

This case report describes the finding of EDTA-dependent Pseudothrombocytopenia in an 8month-old infant, an extremely rare condition not reported in the literature. The patient presented with a fever due to insect bite and was diagnosed with abscessed cellulitis. A complete blood count showed a thrombocytopenia of 47 mil/L, with no history of bleeding or hematologic disease. The following day a new test was performed, which showed a platelet count of 214 mil/L, which was not consistent with the expected evolution of a real thrombocytopenia. Pseudothrombocytopenia was suspected and confirmed by observing platelet aggregates in the blood smear and upon recounting in a tube with sodium citrate, showed a normal value of 298 mil/L. Treatment consists of avoiding the use of EDTA as an anticoagulant and using other anticoagulants such as citrate or heparin. Timely identification of this phenomenon is essential to avoid diagnostic confusion and unnecessary or harmful treatment. This case brings to the scientific literature an example of EDTA-dependent Pseudothrombocytopenia in a pediatric patient, which can be easily confused with other causes of thrombocytopenia and requires a high index of clinical suspicion.

Resumen

Este reporte de caso describe el hallazgo de Pseudotrombocitopenia dependiente de EDTA en un lactante menor de 8 meses, una condición extremadamente rara que no se encuentra reportada en la literatura. El paciente presentó un cuadro febril por picadura de insecto y se le diagnosticó celulitis abscedada. Al realizarle un hemograma se observó una trombocitopenia de 47 mil/L, sin antecedentes de sangrado o enfermedad hematológica. Al día siguiente se le realizó una nueva prueba, que mostró un conteo plaquetario de 214 mil/L, lo que no concordaba con la evolución esperada de una trombocitopenia real. Se sospechó de Pseudotrombocitopenia y se confirmó al observar agregados plaquetarios en el frotis sanguíneo y al realizar el recuento en un tubo con citrato de sodio, que mostró un valor normal de 298 mil/L. El tratamiento consiste en evitar el uso de EDTA como anticoagulante y utilizar otros como citrato o heparina. La identificación oportuna de este fenómeno es esencial para evitar confusiones diagnósticas y tratamientos innecesarios o perjudiciales. Este caso aporta a la literatura científica un ejemplo de Pseudotrombocitopenia dependiente de EDTA en un paciente pediátrico, que puede ser fácilmente confundida con otras causas de trombocitopenia y que requiere un alto índice de sospecha clínica.



Copyright: ©2023 for the authors. This article is open access and distributed under the terms and conditions of the international license Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-ND nd/4.0/deed.es

Introduction

Thrombocytopenia is defined as a platelet count below 150,000/mL [1]. According to its mechanism of action, it can be caused by: *i*) defective production; *ii*) accelerated destruction; *iii*) abnormal distribution and *iii*) artificial thrombocytopenia or pseudothrombocytopenia[2].

Pseudothrombocytopenia (PTCP) is the finding of spuriously low platelet counts, first described in 1969 [3]; it is a well-known phenomenon regularly observed in the hematology laboratory, its prevalence ranges from 0.01 to 1% [4,5] and it is thought to be present in 0.1%-0.2% of the general population [6,7].

It is most commonly seen in women under 50 years of age, and there is a slight male predominance in age groups over 50 years [8]. The main causes of Pseudothrombocytopenia are: *i*) problems in sample collection and processing (inadequate shaking of tubes, dilution of samples, difficulties in peripheral blood collection); ii) giant platelet syndrome; iii) induction by anticoagulants, such as ethylenediaminetetraacetic acid (EDTA), citrate, oxalate and heparin; iv) autoimmune diseases; v) drugs; vi) solid tumors and vii) proliferative syndromes [9].

EDTA-dependent pseudothrombocytopenia, which is the anticoagulant recommended by the International Council for Standardization in Hematology (ICSH) for the performance of hematology [10], is a laboratory phenomenon due to the presence of antiplatelet antibody in the patient's serum. The antibody targets a cryptic antigen within the surface of glycoprotein IIb/IIIa that is revealed only when the glycoprotein undergoes a conformational change in the presence of EDTA. To suspect this condition, 5 criteria must be met: i) abnormal platelet count, typically < 100mil/mL; ii) thrombocytopenia with EDTA, but to a much lesser extent in samples collected with other anticoagulants; iii) decreasing platelet count over time in the EDTA sample; iv) platelet aggregates and clumping in EDTA samples; v) absence of signs or symptoms of platelet disorders. Reliable and timely identification of this phenomenon is essential, as there is a high probability that it can be confused with other disorders or lead to inappropriate decision making [11].

Studies have shown that this phenomenon is not necessarily associated with any disease, and patients do not show any clinical features of thrombocytopenia, but it may rarely be a chance finding in association with a disease or syndrome [8].

Case presentation

An 8-month-old male patient, with no significant personal or family history, was admitted to the emergency department in his mother's arms, who conducted the interview, and manifested a clinical picture of 2 days' evolution consisting of an insect bite in the areolar region of the left breast. Subsequently, the patient presented with febrile peaks of 38.5°C, associated with uncontrollable crying and hyporexia. He did not report any other associated symptoms. He was self-medicated by his mother with paracetamol syrup 150mg/5mL, 5cc orally every 6 hours.

Physical examination showed preserved vital functions, temperature with fever peak of 38.5°C, blood pressure (mmHg): 80/65, mean arterial pressure (mmHg): 70, heart rate (beats/min): 120, respiratory rate (resp/min): 30, oxygen saturation: 98%, with presence of febrile facies and dehydrated mucous membranes. On inspection of the chest in the left breast there was an insect bite in the areolar region, on superficial palpation with inflammatory signs: redness, heat, pain, induration, functional limitation and with the presence of purulent material, measuring approximately 5 x 6 cm, mobile, flexible, rounded shape with well-defined edges, with a smooth surface and purulent cystic consistency, without the presence of secretions, petechiae or rash. In lower limbs presence of multiple mosquito bites. Nervous system alert, without presence of neurological, motor or sensory focalization.


On admission, the patient underwent a complete blood count (CBC), C-reactive protein (CRP), sodium (Na), potassium (K). The paraclinical report showed a hemogram with leukocytosis 16,460, lymphocytes 58.1%, hemoglobin 11.3, hematocrit 34.6 and platelets 47,000, drawing attention to the presence of moderate thrombocytopenia. At that moment a viral condition was suspected due to the presence of febrile peaks plus thrombocytopenia and it was decided to send the patient for renal and hepatic function, coagulation time, IgM and IgG for dengue and arbovirus antigen. These last tests reported preserved renal function, liver function with slight elevation of AST, non-extended times, negative dengue IgG, negative IgM and negative arbovirus (see Table 1).


Table 1. Laboratories

Test name	Results	Reference
Hemograma Automatizado III		range
recuento de glóbulos blancos	16.46	5.00 -
redento de giobulos biancos	10.40	10.00
recuento de glóbulos rojos	4.37	4.00 - 5.00
linfocitos (%)	58.1	17.0 - 49.0
linfocitos (#)	9.59	0.90 - 4.90
monocitos (%)	6.9	3.0 - 12.0
monocitos (#)	1.07	0.20 - 1.20
neutrófilos (%)	30.5	55.0 - 70.0
neutrófilos (#)	4.77	2.80 - 7.00
eosinófilos (%)	0.1	0.0 - 5.0
eosinófilos (#)	0.01	0.00 - 0.50
basófilos (%)	0.3	0.0 - 2.0
basófilos (#)	0.05	0.00 - 0.20
volumen corpuscular medio	0.05 72 fL	80 - 137
hemoglobina corpuscular media (mch)	23.8 pg	27.0 - 32.0
concentración de hemoglobina	23.8 pg 32 g/dl	27.0 - 32.0 31 - 34
corpuscular media (mchc)	52 g/ui	51 - 54
		60 100
volumen plaquetario medio (mpv) rdw cv	15.8	6.0 - 10.0 11.5 - 15.0
hematocrito	34.6	36.0 - 45.0
hemoglobina	11.3 g/dl	12.0 - 15.0
recuento de plaquetas	47	150 - 450
proteína c reactiva	25	
Electrolitos	127	127.0
Sodio en suero	137	137.0-
	mmol/L	145.0
Potasio en suero	4.8	3.5-5.1
<u> </u>	mmol/L	
Química	202 117	120 246
deshidrogenasa láctica	392 U/L	120 - 246
.nitrógeno	11.00	
ureico	mg/dl	
.transaminasa glutámico-piruvica	20 U/L	0-50
(alanino aminotransferasa)		
transaminasa glutamino oxalacetica.	70 U/L	14-36
(aspartato aminotransferasa)		
.creatinina en suero u otros fluidos	0.30	
	mg/dl	
Coagulación		
tiempo de protrombina (pt)		
 plasma control pt 	11.2 seg	
· inr	1.29	
 tiempo de protrombina (pt) 	13.3 seg	9.9 - 11.8
tiempo de tromboplastina parcial (ttp)		
 plasma control ptt 	27.0 seg	
· tiempo de tromboplastina parcial	25.4 seg	24.5 - 32.8
(ttp)		
Pruebas especiales		
Arbovirus antígeno semiautomatizado o	0.29	Negativo:
automatizado		<1.0
		Positivo: \geq
		1.0
Inmunología		
Dengue anticuerpos ig g	Negativo	Negativo
Dengue anticuerpos ig m	Negativo	Negativo
· · ·	-	

The initial diagnosis was abscessed cellulitis and thrombocytopenia under investigation. She was admitted to the paediatric ward with the following medical management: breastmilk diet plus complementary feeding, ringer lactate 500cc to pass at a rate of 42 cc/hour, paracetamol syrup 150 mg/5 cc give 5 cc orally every 6 hours if there is fever or pain, clindamycin amp 600 mg/4 cc apply 100 mg intravenous (IV) slowly diluted every 6 hours, Apply fusidic acid cream 2% every 8 hours to the lesion, monitor in the outpatient clinic the following day: CBC, AST, ALT, electrolytes, LDH, nursing care, report any changes, monitor vital signs.

Control blood tests showed a platelet count of 214,000, which was inconsistent with the patient's clinical symptoms due to an increase of 4 times the initial value. A manual platelet count was therefore requested and 205,000 directly observed platelet aggregates were reported as shown in Figure 1, suggesting a diagnosis of sticky platelets or Pseudothrombocytopenia (see Table 2).





Wright's staining shows platelet adhesion around neutrophils, an in vitro phenomenon known as platelet satelitism. This means that CD16 (FCRIIIa) is a receptor present on the surface of neutrophils that is involved in the phenomenon of platelet satelitism observed in the peripheral blood smear when EDTA is used as an anticoagulant to analyse a haemogram.

Given the variability of platelet concentrations on two consecutive days and the absence of changes in coagulation values, signs of bleeding or thrombotic events, a false thrombocytopenia was suspected. To confirm this diagnosis, laboratory samples were requested in different tubes with different reagents, sodium citrate and EDTA. Blood biometry in a sodium citrate tube showed a normal platelet count of 286,000/mm³ and a manual platelet count of 298,000/mm³ with a normal platelet curve. There were no platelet aggregates in the smear of this sample, the EDTA reactant reported a platelet count of 69,000/mm³, with platelet aggregates, a small platelet curve, both samples are compared as shown in Figures 2,3.

Table 2. Laboratories

Hemograma Automatizado III Image: constraint of the second			range
recuento de glóbulos blancos 15.34 5.00 $-$ recuento de glóbulos rojos 4.43 $4.00 - 5.00$ linfocitos (%) 64.1 $17.0 - 49.0$ linfocitos (%) 9.84 $0.90 - 4.90$ monocitos (%) 3.3 $3.0 - 12.0$ monocitos (%) 3.3 $3.0 - 12.0$ neutrófilos (%) 32.4 $55.0 - 70.0$ neutrófilos (%) 0.02 $0.00 - 0.50$ eosinófilos (%) 0.1 $0.0 - 2.0$ basófilos (%) 0.1 $0.0 - 2.0$ volumen corpuscular medio 71 fl $80 - 137$ hemoglobina corpuscular media (mch) 23.5 pg $27.0 - 32.0$ concentración de hemoglobina 32 g/dl $31 - 34$ corpuscular media (mchc) $yolumen$ plaquetario medio (mpv) 9.4 fl $6.0 - 10.0$ rdw cv 15.7 $11.5 - 15.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 214 $150 - 450$ /mm3 se observan agregados plaquetarios 205 $150 - 450$ recuento de plaquetas 5.0 $3.5 $	Hemograma Automatizado III		
recuento de glóbulos rojos 4.43 4.00 - 5.00 linfocitos (%) 64.1 17.0 - 49.0 linfocitos (#) 9.84 0.90 - 4.90 monocitos (#) 0.51 0.20 - 1.20 monocitos (#) 0.51 0.20 - 1.20 neutrófilos (%) 32.4 55.0 - 70.0 neutrófilos (%) 0.0 0.0 - 5.0 eosinófilos (%) 0.0 0.00 - 0.50 basófilos (%) 0.1 0.0 - 2.0 basófilos (%) 0.1 0.0 - 2.0 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 corouscular media (mch) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 /mm3 se observan agregados plaquetarios 205 150 - 450 mmol/1 145.0 137.0- mmol/1 sodio en suero u otros fluidos 137.0 137.0- mmol/1 145.0 137.0-		15.34	5.00 -
linfocitos (%) 64.1 17.0 - 49.0 linfocitos (#) 9.84 0.90 - 4.90 monocitos (%) 3.3 3.0 - 12.0 monocitos (#) 0.51 0.20 - 1.20 neutrófilos (%) 32.4 55.0 - 70.0 neutrófilos (%) 32.4 55.0 - 70.0 neutrófilos (%) 0.0 0.0 - 2.0 eosinófilos (%) 0.1 0.0 - 2.0 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mch) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hematocrito 31.8 36.0 - 45.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 205 150 - 450 recuento de plaquetas 214 150 - 450 /mm3 se observan agregados plaquetarios Química 137.0 137.0- mmol/l sodio en suero u otros fluidos 137.0 137.0-	e		10.00
linfocitos (%) 64.1 $17.0 - 49.0$ linfocitos (#) 9.84 $0.90 - 4.90$ monocitos (%) 3.3 $3.0 - 12.0$ monocitos (#) 0.51 $0.20 - 1.20$ neutrófilos (%) 32.4 $55.0 - 70.0$ neutrófilos (#) 4.96 $2.80 - 7.00$ eosinófilos (%) 0.0 $0.0 - 5.0$ eosinófilos (%) 0.1 $0.0 - 2.0$ basófilos (%) 0.1 $0.0 - 2.0$ basófilos (%) 0.1 $0.0 - 2.0$ basófilos (%) 0.1 $0.0 - 2.0$ volumen corpuscular media (mch) 23.5 pg $27.0 - 32.0$ concentración de hemoglobina 32 g/dl $31 - 34$ corpuscular media (mchc) 31.8 $36.0 - 45.0$ volumen plaquetario medio (mpv) 9.4 fl $6.0 - 10.0$ rew ev 15.7 $11.5 - 15.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 205 $150 - 450$ recuento de plaquetas 205 $150 - 450$ mmol/l mmol/l 145.0 </td <td>recuento de glóbulos rojos</td> <td>4.43</td> <td>4.00 - 5.00</td>	recuento de glóbulos rojos	4.43	4.00 - 5.00
monocitos (%) 3.3 3.0 - 12.0 monocitos (#) 0.51 0.20 - 1.20 neutrófilos (%) 32.4 55.0 - 70.0 neutrófilos (#) 4.96 2.80 - 7.00 eosinófilos (%) 0.0 0.0 - 5.0 eosinófilos (%) 0.1 0.0 - 2.0 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 immol/l immol/l se observan agregados plaquetarios 205 150 - 450 immol/l potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/l sodio en suero u otros fluidos 137.0 137.0- mmol/l sodio en suero u otros fluidos 137.0		64.1	17.0 - 49.0
monocitos (#) 0.51 0.20 - 1.20 neutrófilos (%) 32.4 55.0 - 70.0 neutrófilos (#) 4.96 2.80 - 7.00 eosinófilos (%) 0.0 0.0 - 5.0 eosinófilos (%) 0.1 0.0 - 2.0 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 corpuscular media (mch) 23.5 pg 27.0 - 32.0 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 mmol/1 mmol/1 sodio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/1 sodio en suero u otros fluidos 137.0 - mmol/1 145.0 transaminasa glutámico-piruvica 24 u/1 0-50 <	linfocitos (#)	9.84	0.90 - 4.90
neutrófilos (%) 32.4 55.0 -70.0 neutrófilos (#) 4.96 2.80 -7.00 eosinófilos (%) 0.0 0.0 -5.0 eosinófilos (%) 0.1 0.0 -2.0 basófilos (%) 0.1 0.0 -2.0 basófilos (%) 0.1 0.0 -2.0 volumen corpuscular medio 71 fl 80 -137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 -32.0 concentración de hemoglobina 32 g/dl 31 - 34 -34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 -15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 recuento de plaquetas 5.0 3.5 - 5.1 mmol/1 145.0 137.0- potasio en suero u otros fluidos 137.0 137.0- mol/1 145.0 145.0 144 transaminasa <td< td=""><td>monocitos (%)</td><td>3.3</td><td>3.0 - 12.0</td></td<>	monocitos (%)	3.3	3.0 - 12.0
neutrófilos (#) 4.96 2.80 - 7.00 eosinófilos (%) 0.0 0.0 - 5.0 eosinófilos (#) 0.00 0.00 - 0.50 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 netatocrito 31.8 36.0 - 45.0 job - 450 job - 450 recuento de plaquetas 214 150 - 450 job - 450 recuento de plaquetas 205 150 - 450 jmmol/1 se observan agregados plaquetarios Mmmol/1 job - 450 job - 450 recuento de plaquetas 137.0 137.0- jmmol/1 job - 450 se observan agregados plaquetarios 137.0 job - 450 job - 450 functa 137.0 137.0- <td< td=""><td>monocitos (#)</td><td>0.51</td><td>0.20 - 1.20</td></td<>	monocitos (#)	0.51	0.20 - 1.20
eosinófilos (%) 0.0 0.0 - 5.0 eosinófilos (#) 0.00 0.00 - 0.50 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 recuento de plaquetas 205 150 - 450 /mm3 se observan agregados plaquetarios Química 101.00 mmol/1 mmol/1 5.0 3.5 - 5.1 sodio en suero u otros fluidos 137.0 137.0- mmol/1 145.0 transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) 14-36	neutrófilos (%)	32.4	55.0 - 70.0
eosinofilos (#) 0.00 0.00 - 0.50 basófilos (%) 0.1 0.0 - 2.0 basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hemoglobina 36.0 - 45.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 /mm3 se observan agregados plaquetarios Química 101.00 mmol/1 sodio en suero u otros fluidos 137.0 - mmol/1 145.0 transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutámino oxalacetica 63 u/l 14-36	neutrófilos (#)	4.96	2.80 - 7.00
basófilos (%) 0.1 0.0 - 2.0 basófilos (%) 0.1 0.0 - 2.0 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) volumen plaquetario medio (mpv) 9.4 fl 6.0 - 10.0 rdw cv 15.7 11.5 - 15.0 hematocrito 31.8 36.0 - 45.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 /mm3 se observan agregados plaquetarios Química 101.00 mmol/l sodio en suero u otros fluidos 5.0 3.5 - 5.1 sodio en suero u otros fluidos 137.0 - mmol/l 145.0 145.0 transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa 63 u/l 14-36	eosinófilos (%)	0.0	0.0 - 5.0
basófilos (#) 0.02 0.00 - 0.20 volumen corpuscular medio 71 fl 80 - 137 hemoglobina corpuscular media (mch) 23.5 pg 27.0 - 32.0 concentración de hemoglobina 32 g/dl 31 - 34 corpuscular media (mchc) $32 g/dl$ 31 - 34 corpuscular media (mchc) $32 g/dl$ 31 - 34 corpuscular media (mchc) 15.7 11.5 - 15.0 hematocrito 31.8 36.0 - 45.0 hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 150 - 450 recuento de plaquetas 205 150 - 450 recuento de plaquetas 205 150 - 450 mmol/l potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/l sodio en suero u otros fluidos 137.0 mmol/l sodio en suero u otros fluidos 137.0 mmol/l transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutámino oxalacetica 63 u/l 14-36	eosinófilos (#)	0.00	0.00 - 0.50
volumen corpuscular medio71 fl80 - 137hemoglobina corpuscular media (mch) 23.5 pg $27.0 - 32.0$ concentración de hemoglobina 32 g/dl $31 - 34$ corpuscular media (mchc) 32 g/dl $31 - 34$ volumen plaquetario medio (mpv) 9.4 fl $6.0 - 10.0$ rdw cv 15.7 $11.5 - 15.0$ hematocrito 31.8 $36.0 - 45.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ se observan agregados plaquetarios $Mm3$ Química cloro 101.00 mmol/lsodio en suero u otros fluidos 5.0 137.0 $3.5 - 5.1$ mmol/lsodio en suero u otros fluidos 137.0 mmol/l 145.0 transaminasaglutámico-piruvica 24 u/l $0-50$ (alanino aminotransferasa) transaminasa 63 u/l $14-36$	basófilos (%)	0.1	0.0 - 2.0
$\begin{array}{c c} \mbox{hemoglobina corpuscular media (mch)} & 23.5 \mbox{ pg} & 27.0 - 32.0 \\ \mbox{concentración de hemoglobina} & 32 \mbox{g/dl} & 31 - 34 \\ \mbox{corpuscular media (mchc)} & & & & & & \\ \mbox{volumen plaquetario medio (mpv)} & 9.4 \mbox{ fl} & 6.0 - 10.0 \\ \mbox{rdw cv} & 15.7 & 11.5 - 15.0 \\ \mbox{hematocrito} & 31.8 & 36.0 - 45.0 \\ \mbox{hemoglobina} & 10.4 \mbox{ g/dl} & 12.0 - 15.0 \\ \mbox{recuento de plaquetas} & 214 & 150 - 450 \\ \mbox{recuento de plaquetas} & 205 & 150 - 450 \\ \mbox{recuento de plaquetas} & 205 & 150 - 450 \\ \mbox{mmol}/l & 101.00 \\ \mbox{mmol}/l \\ \mbox{potasio en suero u otros fluidos} & 5.0 & 3.5 - 5.1 \\ \mbox{mmol}/l & 145.0 \\ \mbox{transaminasa glutámico-piruvica} & 24 \ u/l & 0 -50 \\ \mbox{(alanino aminotransferasa)} \\ \mbox{transaminasa glutamino oxalacetica} & 63 \ u/l & 14-36 \\ \end{array}$	basófilos (#)	0.02	0.00 - 0.20
concentración de hemoglobina corpuscular media (mchc) 32 g/dl $31 - 34$ volumen plaquetario medio (mpv)9.4 fl $6.0 - 10.0$ rdw cv15.7 $11.5 - 15.0$ hematocrito 31.8 $36.0 - 45.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ se observan agregados plaquetarios 00 mmol/l potasio en suero u otros fluidos 5.0 $3.5 - 5.1$ mmol/l $137.0 137.0 -$ sodio en suero u otros fluidos $137.0 -$ transaminasaglutámico-piruvica 24 u/l transaminasaglutámico xalacetica 63 u/l transaminasaglutamino $0xalacetica$	volumen corpuscular medio	71 fl	80 - 137
corpuscular media (mchc)volumen plaquetario medio (mpv)9.4 fl $6.0 - 10.0$ rdw cv 15.7 $11.5 - 15.0$ hematocrito 31.8 $36.0 - 45.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ genderation 101.00 mmol/lpotasio en suero u otros fluidos 5.0 $3.5 - 5.1$ sodio en suero u otros fluidos 137.0 137.0 -transaminasaglutámico-piruvica 24 u/l $0-50$ (alanino aminotransferasa)transaminasaglutámino $oxalacetica$	hemoglobina corpuscular media (mch)	23.5 pg	27.0 - 32.0
volumen plaquetario medio (mpv)9.4 fl $6.0 - 10.0$ rdw cv15.7 $11.5 - 15.0$ hematocrito 31.8 $36.0 - 45.0$ hemoglobina 10.4 g/dl $12.0 - 15.0$ recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ se observan agregados plaquetarios $\mathbf{Qu'mica}$ cloro 101.00 potasio en suero u otros fluidos 5.0 $3.5 - 5.1$ mmol/1sodio en suero u otros fluidos 137.0 transaminasaglutámico-piruvica 24 u/l $0-50$ (alanino aminotransferasa)transaminasa $14-36$	concentración de hemoglobina	32 g/dl	31 - 34
rdw cv 15.7 11.5 - 15.0 hematocrito 31.8 $36.0 - 45.0$ hemoglobina 10.4 g/dl 12.0 - 15.0 recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ mm3 se observan agregados plaquetarios Química cloro 101.00 mmol/1 potasio en suero u otros fluidos 5.0 $3.5 - 5.1$ mmol/1 sodio en suero u otros fluidos 137.0 $137.0 -$ mmol/1 145.0 transaminasa glutámico-piruvica 24 u/1 0-50 (alanino aminotransferasa) transaminasa glutámino oxalacetica 63 u/1 14-36	corpuscular media (mchc)		
$\begin{array}{ccccc} hematocrito & 31.8 & 36.0 - 45.0 \\ hemoglobina & 10.4 g/dl & 12.0 - 15.0 \\ recuento de plaquetas & 214 & 150 - 450 \\ recuento de plaquetas & 205 & 150 - 450 \\ /mm3 & \\ \hline $	volumen plaquetario medio (mpv)		
$\begin{array}{c cccc} hemoglobina & 10.4 \ g/dl & 12.0 - 15.0 \\ recuento de plaquetas & 214 & 150 - 450 \\ recuento de plaquetas & 205 & 150 - 450 \\ /mm3 & & \\ \hline \end{array}$	rdw cv		
recuento de plaquetas 214 $150 - 450$ recuento de plaquetas 205 $150 - 450$ recuento de plaquetas 205 $150 - 450$ se observan agregados plaquetarios $\mathbf{Química}$ cloro 101.00 mmol/l 5.0 sodio en suero u otros fluidos 5.0 sodio en suero u otros fluidos 137.0 transaminasa $glutámico-piruvica$ $24 u/l$ $0-50$ (alanino aminotransferasa) $14-36$			
recuento de plaquetas 205 150 - 450 /mm3 constraints a glutámico-piruvica 24 u/1 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/1 14-36	hemoglobina	10.4 g/dl	
Provide of purpletation Provide of purpletation Se observan agregados plaquetarios Provide of purpletation Química Internetation cloro 101.00 potasio en suero u otros fluidos 5.0 sodio en suero u otros fluidos 5.0 transaminasa glutámico-piruvica (alanino aminotransferasa) 145.0 transaminasa glutámino transaminasa glutámino			
se observan agregados plaquetarios Química cloro 101.00 mmol/l potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/l sodio en suero u otros fluidos 137.0 137.0- mmol/l transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutámino 0xalacetica 63 u/l 14-36	recuento de plaquetas	200	150 - 450
Química cloro 101.00 mmol/1 potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/1 sodio en suero u otros fluidos 137.0 137.0- mmol/1 transaminasa glutámico-piruvica 24 u/1 0-50 (alanino aminotransferasa) transaminasa glutamino 0xalacetica 63 u/1 14-36		/mm3	
cloro101.00 mmol/1potasio en suero u otros fluidos5.03.5 - 5.1 mmol/1sodio en suero u otros fluidos137.0137.0- mmol/1transaminasaglutámico-piruvica24 u/10-50(alanino aminotransferasa) transaminasa63 u/114-36			
mmol/l potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/l sodio en suero u otros fluidos 137.0 137.0- mmol/l 145.0 transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/l 14-36	Química		
potasio en suero u otros fluidos 5.0 3.5 - 5.1 mmol/1 sodio en suero u otros fluidos 137.0 137.0- mmol/1 145.0 transaminasa glutámico-piruvica 24 u/1 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/1 14-36	cloro		
mmol/1 sodio en suero u otros fluidos 137.0 137.0- mmol/1 145.0 transaminasa glutámico-piruvica 24 u/1 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/1 14-36			
sodio en suero u otros fluidos137.0137.0-mmol/1145.0transaminasaglutámico-piruvica24 u/l0-50(alanino aminotransferasa)transaminasaglutamino14-36	potasio en suero u otros fluidos	010	3.5 - 5.1
mmol/1 145.0 transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/l 14-36		mmol/l	
transaminasa glutámico-piruvica 24 u/l 0-50 (alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/l 14-36	sodio en suero u otros fluidos	10/10	
(alanino aminotransferasa) transaminasa glutamino oxalacetica 63 u/l 14-36			
transaminasa glutamino oxalacetica 63 u/l 14-36		24 u/l	0-50
(aspartato aminotransferasa)		63 u/l	14-36
	(aspartato aminotransferasa)		

Pral Graf. Acumulat. Q-Flag Service CBC Dato 14.69 4.66 10.7 34.1 73.2 23.0 31.4 286 41.6 15.9 9.3 0.00 0.0 Unid tipo WBC RBC HGB HCT MCV MCH MCHC PLT RDW-SD RDW-CV Dato 1.45 12.18 0.44 0.56 0.03 10^3/u 10^6/u g/dL % LYMPH MONO# EO# BASO# NEUT% fL pg g/d 10^ fL % fL 9. 82.1 3.0 3.8 EO% BASO NRBC# IG# IG%

Figure 2. Automated blood count. A- (CITRATE)

Automated blood count is performed from a tube with sodium citrate anticoagulant, which reports a normal platelet count (286,000/mm³). The histogram shows that there is an increase in curvature, with a subsequent decrease as the platelets increase in size. This indicates that the platelets are of adequate size (Mean platelet volume MPV normal).

Pseudothrombocytopenia due to platelet aggregates in an infant: A case report

to Unid .26 + 10^3/uL .07 10^6/uL 1.6 g/dL	DIFF tipo NEUT# LYMPH#	Dato Unid 1.69 * 10^3/uL			
.26 + 10^3/uL .07 10^6/uL	NEUT#	1.69 * 10^3/uL			1
.07 10^6/uL					
	LYMPH#				
1.6 a/di		13.06 * 10^3/uL			
	MONO#	0.84 * 10^3/uL			
6.9 %	EO#	0.59 + 10^3/uL			
					/
			/ N		
					/
	10.9	0.1 - X		~	
0.0 %					· ·
	2.8 - fL 2.9 - pg 1.4 g/dL 69 * 10 ³ /uL 1.6 fL 5.9 % 0.7 * fL .00 10 ³ /uL 0.0 %	2.9 - pg NEUT% 1.4 g/dL LYMPHK 69 * 10*3/uL MONOK 1.6 fL EOK 5.9 % BASOK 0.7 * fL IG# 0.60 10*3/uL IG%	2.9 pg NEUTX 10.4 4 % 1.4 g/dL LVMPKK 88.3 * % 6.8 10*3/uL NONOK 5.2 * % 5.9 % BASOK 0.4 % 5.9 % BASOK 0.4 % 1.6 #L ICS 0.4 % 5.9 % BASOK 0.4 % 0.8 * 16*3 0.2 * 10*3/uL 0.2 IGS 0.2 * 10*3/uL 0.1 * % %	2.9 - [pg] NEUTX 10.4 * X 69 * 10*3/uL (VMPKX 83.4 × 66 * 10*3/uL (MONOK 5.2 * X 5.9 X (BASOK 0.4 - X 5.9 X (BASOK 0.4 - X 10* 0.4 - X (BASOK 0.4 - X (BA	2.9 - pg 1.4 g/dL L/DPHK 80.3 * % 69 * 10*3/uL 1.6 ft 85.2 * % ECK 3.6 fX 85.2 * % 1.6 ft 85.2 * % 1.6 ft 1.6 ft 1.6 ft 1.6 g/L 1.6 ft 1.6 g/L 1.6 g/

Subsequent biometrics were performed in sodium citrate tubes and showed platelet counts within normal ranges. Pseudothrombocytopenia induced by an immunological reaction to EDTA reagent was diagnosed and it was recommended that all samples be collected in sodium citrate tubes.

The patient received intravenous antibiotic treatment with clindamycin for 5 days with resolution of the abscessed cellulitis. Topical treatment with fusidic acid cream 2% was continued for 7 days and adequate wound healing was observed. Temperature, pain and fluid control were maintained with paracetamol and lactated Ringer's solution. The mother was educated insect possible about bite prevention and complications. Finally, the patient was discharged from paediatrics with wound care instructions and attended a haematology appointment where the diagnosis of EDTA-induced pseudothrombocytopenia (EDTA-PTCP) was confirmed.

Discussion

This is case report of EDTA-dependent а pseudothrombocytopenia (EDTA-PTCP) in an 8month-old infant, an extremely rare condition that has not been reported in the literature in younger infants. However, it is important to note that approximately 0.1% of the world's population has natural EDTAdependent antiplatelet antibodies [12]. The patient was referred to the clinical laboratory because of a thrombocytopenia of 47 mil/L in a test requested after admission to the emergency department for febrile symptoms due to insect bites, with no history of bleeding, haematological disease or infection to explain the symptoms. A new test was performed the following day and showed a platelet count of 214 mil/L, which

was not consistent with the expected evolution of a true thrombocytopenia. There are no data on the incidence or prevalence of EDTA-dependent antibodies in this population. Most of the cases described in the literature are adults, especially women [13].

This case has some peculiarities that make it of interest to the scientific community. Firstly, the thrombocytopenia occurred abruptly in the initial platelet count, and no gradual decrease was observed when testing was performed. This may suggest that EDTA-induced platelet agglutination is a variable phenomenon, dependent on sample conditions, and that most cases have an unknown aetiology. It also contrasts with what was reported in the study by Morales et al. [13], where a progressive decrease in platelet count was observed in EDTA samples. In addition, despite advances in automated blood analysers, new methods still fail to detect platelet aggregation and satellitism, leading to a false decrease in platelet count [6,14,15]. It is recommended to suspect PTCP-EDTA in any discrepancy between automated platelet count and blood smear to avoid false positive thrombocytopenia and to guide appropriate treatment.

pseudothrombocytopenia EDTA-induced has а physiological mechanism that is not yet well understood, but there are studies suggesting that the autoantibodies present in plasma in the presence of EDTA recognise and bind to the epitope of glycoprotein IIb (GPIIb), forming the GPIIb/IIIa complex in platelet aggregation and promoting platelet agglutination [6,16,17]. The important thing about this problem is that these patients do not show clinical data of thrombocytopenia and no alterations in coagulation tests are found, so it is important to consider this disorder in order to avoid unnecessary therapeutic measures that could have serious adverse effects that would only complicate the patient's situation. A study has recently been published comparing patients with pseudothrombocytopenia and healthy individuals (n = 49 patients vs. n = 69 controls). Most of the patients were hospitalised (61%) and there were no significant differences between the groups in terms of the characteristics studied, except that the group of patients with pseudothrombocytopenia was more likely to use low-molecular-weight heparin [2].

The importance of microscopic examination of the blood smear is evident in any suspected PTCP-EDTA, as the presence of platelet clusters is the hallmark of this phenomenon. The diagnosis is based on the microscopic observation of platelet clusters, which may have different shapes and sizes, and which dissociate when the anticoagulant is changed or when antiaggregant agents are added [13,18,19,20].

Thirdly, treatment consists of avoiding the use of EDTA as an anticoagulant and using other anticoagulants such as citrate or heparin. Kanamycin, which has been shown to be effective in preventing IgG-mediated platelet agglutination, may also be used. The use of alternative anticoagulants to EDTA, such as sodium citrate, oxalate or heparin, is a good option to exclude EDTA-induced pseudothrombocytopenia, but there are some rare cases of pseudothrombocytopenia associated with these anticoagulants. Other procedures less commonly used in laboratory practice to confirm cases of pseudothrombocytopenia include reanalysis of the sample collected in EDTA after incubation at 37°C for about 30 minutes (the purpose of this incubation is to dissociate platelet aggregates), or addition of certain aminoglycosides such as kanamycin and amikacin to the EDTA-collected sample (these do not affect the cell count and prevent the formation of platelet aggregates, although their mechanism of action is not yet well understood) [9].

Conclusion

In the case report, the patient showed a favourable evolution of his initial symptoms without complications or sequelae. The prognosis is good, considering that PTCP-EDTA is a benign and transient condition that does not require specific treatment and does not pose a risk of bleeding or thrombosis. It has been recommended that blood samples requiring platelet count be taken using a sodium citrate tube. The patient is expected to have a normal quality of life.

EDTA-dependent pseudothrombocytopenia is a rare phenomenon but should be considered in the differential diagnosis of thrombocytopenia, especially in patients without clinical signs of bleeding or haematological disease. This condition is caused by the formation of platelet aggregates in the presence of EDTA, which interfere with automated platelet counting. To avoid this error, it is recommended to use other anticoagulants such as citrate, to add amikacin to the sample to reverse platelet agglutination, or to perform a manual count on the smear.

Early recognition of this phenomenon is essential to avoid unnecessary interventions, such as platelet transfusions or invasive tests, which can put the

Pseudothrombocytopenia due to platelet aggregates in an infant: A case report

patient's health at risk. It can also reduce the length of hospital stay and costs associated with the management of thrombocytopenia. This case provides an example of EDTA-dependent pseudothrombocytopenia or pseudothrombocytopenia in a young infant, which has not been previously reported in the literature, and illustrates the importance of clinical correlation and medical judgement for correct diagnosis and exclusion of true thrombocytopenia.

Abbreviations

ALT: alanine aminotransferase AST: aspartate transaminase CBC: complete blood count CRP: C-reactive protein EDTA: ethylenediaminetetraacetic acid GPIIb: glycoprotein IIb ICSH: International Council for Standardization in Hematology IV: intravenous LDH: Lactate dehydrogenase PTCP: Pseudothrombocytopenia MPV Mean platelet volume.

Consent for publication

The authors read and approved the final manuscript.


Competing interest

The authors declare no conflict of interest. This document only reflects their point of views and not that of the institution to which they belong.

Author details

Esteban Artunduaga Cañas

Fifth year medical student at the Unidad Central del Valle del Cauca, Colombia. Passionate about research in haematology, surgery and internal medicine. I am a member of the Centre for Research in Communicable



Infectious Diseases (EINTRANS) of the Department of the Faculty of Health, with national and institutional recognition in research.

Esteban Pineda Arias

Fourth year medical student at the Unidad Central del Valle del Cauca, Colombia. I am a member of the Communicable Diseases Research Centre (EINTRANS) in the Department of Health Sciences of the UCEVA.



Estefania Rivera Velásquez

Fifth year medical student at the Unidad Central del Valle del Cauca UCEVA, Colombia. I am passionate about research and analysing issues, and my goal is to actively participate in research projects that contribute to the development of medicine and science.



My focus is to actively participate in research projects in this field, contributing to the advancement of knowledge in the field of medicine.

Juan Sebastián Arango Duque

Fifth year medical student at the Unidad Central del Valle del Cauca UCEVA, Colombia. Interested in the field of research in emerging diseases, hemat-oncology and surgery. Active member of the Research Group on Communicable Sciences of the UCEVA.



Diego Fernando López Muñoz

Professor at the Faculty of Health Sciences of the Central Unit of Valle del Cauca, Colombia. Bacteriologist of the Catholic University of Manizales. MsC in Biomedical Sciences from the University of Castilla-La Mancha, Spain and Specialist in Transfusion



Medicine from the Autonomous University of Barcelona, Spain. He is currently the director of the Research Group on Communicable Infectious Diseases ENITRANS.

References

[1] Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician 2012;85:612–22. PMID: 22534274.

[2] Reibán Espinoza EA, Sanmartín Calle YA, Reibán Sanmartín EA. Trombocitopenia por agregados plaquetarios: reporte de caso. Revista de La Facultad de Ciencias Médicas de La Universidad de Cuenca 2020;38:65–71. https://doi.org/10.18537/RFCM.38.01.09

[3] Gowland E, Kay HEM, Spillman JC, Williamson JR. Agglutination of platelets by a serum factor in the presence of EDTA. J Clin Pathol 1969;22:460–4. https://doi.org/10.1136/jcp.22.4.460

[4] Schuff-Werner P, Mansour J, Gropp A. Pseudothrombocytopenia (PTCP). A challenge in the daily laboratory routine? Journal of Laboratory Medicine 2020;44:295–304. https://doi.org/10.1515/labmed-2020-0099

[5] Zandecki M, Genevieve F, Gerard J, Godon A. Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. Int J Lab Hematol 2007;29:21–41. https://doi.org/10.1111/j.1365-2257.2006.00871.x

[6] Nagler M, Keller P, Siegrist D, Alberio L. A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon. BMC Clin Pathol 2014; 14:19. https://doi.org/10.1186/1472-6890-14-19

[7] Silvestri F, Virgolini L, Savignano C, Zaja F, Velisig M, Baccarani M. Incidence and Diagnosis of EDTA-Dependent Pseudothrombocytopenia in a Consecutive Outpatient Population Referred for Isolated Thrombocytopenia. Vox Sang 1995;68:35– 9. https://doi.org/10.1111/j.1423-0410.1995.tb02542.x.

[8] Bizzaro N. EDTA-dependent pseudothrombocytopenia: A clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995;50:103–9. https://doi.org/10.1002/ajh.2830500206

[9] Costa BMB, Vellés MC, Viana MMFB, Pereira ACM, Rocha SCP, Rocha LP, et al. Thrombogram: case report of pseudothrombocytopenia. J Bras Patol Med Lab 2020;56. https://doi.org/10.5935/1676-2444.20200005

[10] England JM, Rowan RM, van Assendelft OW, Bull BS, Coulter W, Fujimoto K, et al. Recommendations of the International Council for Standardization in Haematology for Ethylenediaminetetraacetic Acid Anticoagulation of Blood for Blood Cell Counting and Sizing: International Council for Standardization in Haematology: Expert Panel on Cytometry. Am J Clin Pathol 1993; 100:371–2. https://doi.org/10.1093/ajcp/100.4.371

[11] Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med 2012;50. https://doi.org/10.1515/cclm-2012-0081

[12] Greenberg L., EM, S., Kaled ES. Thrombocytopenia. Crit Care Nurs Clin North Am 2013;25:427–34. https://doi.org/10.1016/j.ccell.2013.08.003 [13] Morales M, Moreno A, Mejía M, Bustamante Y. Pseudotrombocitopenia edta-dependiente: Rol del laboratorio clínico en la detección y el correcto contaje plaquetario. Revista de La Facultad de Medicina 2001;24.

http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0798-04692001000100008

[14] Kovacs F, Varga M, Pataki Z, Rigo E. Pseudothrombocytopenia with multiple anticoagulant sample collection tubes. Interv Med Appl Sci 2016; 8:181–3. https://doi.org/10.1556/1646.8.2016.4.4

[15] Kim Hj, Moh Ih, Yoo H, Son S, Jung Dh, Lee Hg, et al. Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia associated with neuroendocrine carcinoma: A case report. Oncol Lett 2012; 4:86–8. https://doi.org/10.3892/ol.2012.675

[16] Lewis S, Bain B, Bates I. Hematología práctica de Dacie y Lewis. 9th ed. Porto Alegre, Brasil: Artmed; 2006.

[17] Carrillo Esper R, Morales Victorino N, Ramírez Rosillo F. Pseudotrombocitopenia: reporte de un caso y revisión de la bibliografía. Med Int Mex 2009; 25:163–8. https://www.medigraphic.com/pdfs/medintmex/mim-2009/mim092i.pdf.

[18] Shabnam I. Ethylenediaminetetraacetic Acid (EDTA) – Dependent Pseudothrombocytopenia: A Case Report. Journal of Clinical and Diagnostic Research 2014. https://doi.org/10.7860/JCDR/2014/9603.5019

[19] MindRay. HemaBook Capítulo 1: Historias de cúmulos plaquetarios. HemaBook 2009.

https://www.mindray.com/mx/media-center/blogs/the-stories-of-platelet-clump#.

[20] Sarasa Bosque C, Arruga Mombiela C, Denizon Arranz S. Aprendiendo de los errores: fenómeno EDTA. SEMERGEN -Medicina de Familia 2009;35:106–7. https://doi.org/10.1016/S1138-3593(09)70430-7